| Name | Title | Contact Details |
|---|
Fullpower is the leader for cloud-based IoT smart-home and wearable solutions powered by AI, machine-learning and data science. With more than 125 patents, the Fullpower IP portfolio covers the AI-powered Sleeptracker® and the MotionX® IoT technology platforms for the Smart-Home and wearable. Fullpower`s business model is to license technology and IP to brand leaders such as Nike, BeautyRest, Amazon, Movado, Serta and others. Founded by Philippe Kahn, creator of the first camera-phone and based in Silicon Valley, the Fullpower team is passionate about technology craftsmanship, innovation, and the global AI-IoT paradigm shift.
FlagHouse is a Hasbrouck Heights, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Astra Tech is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MLS Logistics is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.